The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trastuzumab emtansine as second-line therapy in HER2 positive advanced biliary tract cancers: Single arm prospective phase II clinical trial (TAB-3 trial).
 
Vikas Ostwal
Consulting or Advisory Role - PredOmix Technologies Pvt (Inst)
Research Funding - BDR Pharmaceutics (Inst); Cadila Pharmaceuticals (Inst); Dr. Reddy's Laboratories (Inst); Intas (Inst); Lupin Pharmaceuticals (Inst); NATCO Pharma (Inst); Panacea Pharmaceuticals (Inst); Panacea Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Intas; NATCO Pharma; NATCO Pharma; PredOmix Technologies Pvt
 
Prabhat Bhargava
Honoraria - Intas (Inst); Merck (Inst)
Consulting or Advisory Role - Lupin Pharmaceuticals (Inst); Mankind Pharma (Inst)
Speakers' Bureau - Novartis (Inst); Zydus Pharmaceuticals (Inst)
 
Rajiv Kaushal
No Relationships to Disclose
 
Subhash Yadav
No Relationships to Disclose
 
Gauri Wagh
No Relationships to Disclose
 
Deepali Naughane
No Relationships to Disclose
 
Tejashree Garkal
No Relationships to Disclose
 
Sarika Mandavkar
No Relationships to Disclose
 
Deepali Chaugule
No Relationships to Disclose
 
Anant Ramaswamy
No Relationships to Disclose